Cost Per Responder Analysis from the Checkmate 025 Phase III Trial of Nivolumab Versus Everolimus in Previously Treated Patients with Advanced Renal Cell Carcinoma
Abstract
Authors
JS Liu J Bell R Sumati
JS Liu J Bell R Sumati
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now